

# Nobuaki Ito

## Curriculum Vitae



Project Associate Professor  
 Division of Therapeutic Development for Intractable Bone Diseases, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Japan

### Educational Background & Professional Experience

- 2024.2–Present      Project Associate Professor, Division of Therapeutic Development for Intractable Bone Diseases, The University of Tokyo
- 2018.6–Present      Vice Director, Osteoporosis Center, The University of Tokyo Hospital
- 2014.2–2023.1      Assistant Professor, Division of Nephrology and Endocrinology, The University of Tokyo Hospital
- 2010.4–2014.1      Postdoctoral Fellow, Centre for Orthopaedic & Trauma Research, The University of Adelaide
- 2009.6–2010.3      Staff Endocrinologist, Endocrine Center, Toranomon Hospital
- 2004.4–2008.3      Ph.D student at University of Tokyo School of Medicine
- 2001.5–2004.3      Resident, Department of Internal Medicine, The University of Tokyo Hospital

### Research Interests

I have worked with my supervisor, Seiji Fukumoto, advancing research on FGF23–related disorders, including XLH and TIO. During my graduate studies, I investigated the regulatory mechanisms of FGF23 production and later served as principal investigator for clinical trials of burosumab in XLH and TIO. I have conducted clinical and basic research on rare bone diseases such as hypophosphatasia, osteogenesis imperfecta, osteopetrosis, and Paget’s disease of bone, and have published widely in this field. I also serve on Japanese guideline committees for XLH, HPP, and ACH. In 2025, I identified a new disease concept—autoimmune osteomalacia caused by autoantibodies against PHEX—and reported it in the New England Journal of Medicine. I aim to further advance the understanding of rare bone diseases and develop therapeutic strategies for acquired diseases of unknown cause.

### Publications

1. Srivastava S, ..., Ito N, ..., Braddock DT. The prevalence of ENPP1 deficiency in humans with OPLL and the preclinical efficacy of ENPP1 enzyme therapy in OPLL mice, J Bone Miner Res, 2025.
2. Irie K, Kato H, ..., Ito N, PHEX protein in the parathyroid gland contributes to phosphate sensing, J Clin Endocrinol Metab, 2025.
3. Hoshino Y, Okamoto K, ..., Ito N, Acquired Osteomalacia Associated with Autoantibodies against PHEX, N Engl J Med, 2025.
4. Hidaka N, Inoue K, ..., Ito N, FGF–23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation Analysis. JACC Adv, 2023.
5. Takashi Y, Kosako H, ..., Ito N, ..., Fukumoto S, Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O–glycosylation, Proc Natl Acad Sci U S A, 2019.